NYSE:ZBH - Zimmer Biomet Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$129.56 +2.13 (+1.67 %)
(As of 03/21/2019 04:00 PM ET)
Previous Close$127.43
Today's Range$126.84 - $129.56
52-Week Range$96.99 - $134.55
Volume1.40 million shs
Average Volume1.30 million shs
Market Capitalization$26.49 billion
P/E Ratio16.96
Dividend Yield0.75%
Beta1.23
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and spinal fusion stimulators. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Receive ZBH News and Ratings via Email

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone574-267-6131

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.93 billion
Cash Flow$18.1203 per share
Book Value$55.28 per share

Profitability

Net Income$-379,200,000.00

Miscellaneous

Employees19,000
Market Cap$26.49 billion
Next Earnings Date4/25/2019 (Estimated)
OptionableOptionable

Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions

What is Zimmer Biomet's stock symbol?

Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet announced a quarterly dividend on Thursday, March 7th. Stockholders of record on Friday, March 29th will be given a dividend of $0.24 per share on Tuesday, April 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date of this dividend is Thursday, March 28th. View Zimmer Biomet's Dividend History.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings Inc (NYSE:ZBH) announced its quarterly earnings data on Friday, February, 1st. The medical equipment provider reported $2.18 earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of $2.18. The medical equipment provider had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a negative net margin of 4.78% and a positive return on equity of 13.17%. The business's revenue was up .1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.10 EPS. View Zimmer Biomet's Earnings History.

When is Zimmer Biomet's next earnings date?

Zimmer Biomet is scheduled to release their next quarterly earnings announcement on Thursday, April 25th 2019. View Earnings Estimates for Zimmer Biomet.

What guidance has Zimmer Biomet issued on next quarter's earnings?

Zimmer Biomet updated its FY19 earnings guidance on Friday, February, 1st. The company provided earnings per share guidance of $7.70-7.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.81. The company issued revenue guidance of $7.89-7.97 billion (+/- 0.5%), compared to the consensus revenue estimate of $7.96 billion.Zimmer Biomet also updated its FY 2019 guidance to $7.70-7.90 EPS.

What price target have analysts set for ZBH?

23 brokerages have issued 1-year target prices for Zimmer Biomet's shares. Their forecasts range from $96.00 to $150.00. On average, they anticipate Zimmer Biomet's share price to reach $128.3333 in the next twelve months. This suggests that the stock has a possible downside of 0.9%. View Analyst Price Targets for Zimmer Biomet.

What is the consensus analysts' recommendation for Zimmer Biomet?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 3 sell ratings, 8 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Zimmer Biomet.

What are Wall Street analysts saying about Zimmer Biomet stock?

Here are some recent quotes from research analysts about Zimmer Biomet stock:
  • 1. According to Zacks Investment Research, "Over the past three months, Zimmer Biomet has underperformed its industry. We are concerned about the company's escalating costs and expenses that are exerting considerable pressure on the bottom line. Also, declining dental sales at CER is a drag. Adverse currency movements continue to remain a major headwind for the company. However, post a mixed third quarter by Zimmer Biomet, we are hopeful about the company’s consistent efforts in product and renovation through research and development. Improvement in the company’s global Knee and Hip sales performance and growth in the Asia Pacific region are encouraging. Banking on its focus on priority areas like quality remediation, supply recovery efforts and product launches, Zimmer Biomet reported strong top-line numbers within its S.E.T arm." (1/12/2019)
  • 2. BTIG Research analysts commented, "an easy comp led us to believe that 3Q results were beatable. While top-line fell in-line with the Street and EPS was 3 cents higher (which would have satisfied investors in our view), sentiment was hampered by commentary related to FY19 (specifically ongoing margin pressures and lost sales from ZBH’s distribution agreement with BONESUPPORT (BONEX-OM, Not Rated)). Underlying rev. growth of 2.0% Y/Y improved Y/Y (helped by 3Q tenders, ~40bps by our est.) and while GMs were soft (as expected in 3Q), mgmt. commentary indicates ongoing margin pressure into FY19 along with increasing Fx headwinds. Collectively headwinds will lower EPS by $0.15 in FY19, offset by a lower interest expense and tax rate." (10/28/2018)
  • 3. Needham & Company LLC analysts commented, "In an 8-K filed this morning, ZBH disclosed that it received a FDA warning letter late Friday, 8/24.The warning letter isn’t a surprise in our view given ZBH’s previous two Form 483s. While we think that the risk of a consent decree has probably increased, we still think it is very unlikely given ZBH’s significant efforts and investments in addressing the Biomet plant issues. We don’t expect any impact to ZBH’s financial results from the warning letter and maintain our Buy rating." (8/27/2018)
  • 4. Cantor Fitzgerald analysts commented, "We rate ZBH shares Overweight and have a 12-month price target of $150. ZBH has started a new era with recently hired the CEO of 10 years resigned in July. Under the new CEO near-term challenges persist, but we would expect the company to benefit from Hanson’s broader medtech background. ZBH is the least expensive large-cap medtech stock on a P/E basis, currently trading at a discount to the S&P. We believe the risk/reward is attractive at these levels and think there could be significant upside to shares if ZBH posts a couple of quarters of accelerating growth." (8/27/2018)

Has Zimmer Biomet been receiving favorable news coverage?

News headlines about ZBH stock have trended somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zimmer Biomet earned a news sentiment score of -1.1 on InfoTrie's scale. They also assigned news headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.

Who are some of Zimmer Biomet's key competitors?

What other stocks do shareholders of Zimmer Biomet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zimmer Biomet investors own include Celgene (CELG), General Electric (GE), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Bristol-Myers Squibb (BMY), Teva Pharmaceutical Industries (TEVA), UnitedHealth Group (UNH), AT&T (T), AbbVie (ABBV) and CVS Health (CVS).

Who are Zimmer Biomet's key executives?

Zimmer Biomet's management team includes the folowing people:
  • Mr. Bryan C. Hanson, Pres, CEO & Director (Age 52)
  • Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 55)
  • Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 47)
  • Mr. Sang Yi, Pres of Asia Pacific (Age 57)
  • Mr. Kenneth R. Tripp, Sr. VP of Global Operations & Logistics

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.83%), Massachusetts Financial Services Co. MA (6.66%), Longview Partners Guernsey LTD (3.16%), American Century Companies Inc. (2.66%), Nordea Investment Management AB (1.84%) and Northern Trust Corp (1.76%). Company insiders that own Zimmer Biomet stock include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Chad F Phipps, David C Dvorak, Katarzyna Mazur-Hofsaess, Michael J Farrell, Michael W Michelson, Sang Yi, Syed A Jafry and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet.

Which major investors are selling Zimmer Biomet stock?

ZBH stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Nordea Investment Management AB, Massachusetts Financial Services Co. MA, Eagle Asset Management Inc., Harris Associates L P, Wedge Capital Management L L P NC, Longview Partners Guernsey LTD and Nuveen Asset Management LLC. Company insiders that have sold Zimmer Biomet company stock in the last year include Chad F Phipps, Katarzyna Mazur-Hofsaess and Tony W Collins. View Insider Buying and Selling for Zimmer Biomet.

Which major investors are buying Zimmer Biomet stock?

ZBH stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, American Century Companies Inc., Boston Partners, D. E. Shaw & Co. Inc., Ceredex Value Advisors LLC, Factory Mutual Insurance Co., Geode Capital Management LLC and Prudential Financial Inc.. Company insiders that have bought Zimmer Biomet stock in the last two years include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Michael J Farrell, Michael W Michelson and Syed A Jafry. View Insider Buying and Selling for Zimmer Biomet.

How do I buy shares of Zimmer Biomet?

Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zimmer Biomet's stock price today?

One share of ZBH stock can currently be purchased for approximately $129.56.

How big of a company is Zimmer Biomet?

Zimmer Biomet has a market capitalization of $26.49 billion and generates $7.93 billion in revenue each year. The medical equipment provider earns $-379,200,000.00 in net income (profit) each year or $7.64 on an earnings per share basis. Zimmer Biomet employs 19,000 workers across the globe.

What is Zimmer Biomet's official website?

The official website for Zimmer Biomet is http://www.zimmerbiomet.com.

How can I contact Zimmer Biomet?

Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]


MarketBeat Community Rating for Zimmer Biomet (NYSE ZBH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  664 (Vote Outperform)
Underperform Votes:  556 (Vote Underperform)
Total Votes:  1,220
MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe ZBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel